Authors:Ali Jabbari, Zhenpeng Dai, Luzhou Xing, Jane E. Cerise, Yuval Ramot, Yackov Berkun, Gina A. Montealegre Sanchez, Raphaela Goldbach-Mansky, Angela M. Christiano, Raphael Clynes, Abraham Zlotogorski

Journal: EBioMedicine

Publication Date: February 26, 2015

Volume: 2, Issue: 4, Pages: 351-355

DOI: 10.1016/j.ebiom.2015.02.015

摘要

Abstract : Alopecia areata (AA) is an autoimmune disease characterized by hair loss. This study investigates the efficacy of baricitinib, a JAK1/2 inhibitor, in reversing AA in a patient with concomitant CANDLE syndrome. The treatment resulted in significant hair regrowth, with in vivo studies using a mouse model showing a strong correlation between the resolution of interferon signatures and clinical improvement.

摘要 : 斑秃（AA）是一种导致脱发的自身免疫疾病。本研究探讨了JAK1/2抑制剂Baricitinib在逆转伴有CANDLE综合征的AA患者中的疗效。治疗显著促进了毛发再生，体内小鼠模型研究表明干扰素信号消退与临床改善之间存在强相关性。

化合物及其CAS号

Related Compounds and Their CAS Numbers:

• Baricitinib: 1187594-09-7
• Tofacitinib (托法替布): 477600-75-2
• Ruxolitinib (鲁索利替尼): 941678-49-5
• Fedratinib (Fedratinib): 936091-14-4